Aliases & Classifications for Vascular Dementia

MalaCards integrated aliases for Vascular Dementia:

Name: Vascular Dementia 12 6 15 17 32
Multi-Infarct Dementia 73 53 70 32
Dementia, Vascular 73 44 70
Vascular Dementia, Susceptibility to 6
Dementia - Multi-Infarct 53
Dementia, Multi-Infarct 44
Multi Infarct Dementia 12
Multifocal Dementia 12
Dementia Vascular 54

Classifications:



External Ids:

Disease Ontology 12 DOID:8725
ICD9CM 34 290.4
SNOMED-CT 67 192165000 56267009
ICD10 32 F01 F01.1 F01.9
UMLS 70 C0011263 C0011269

Summaries for Vascular Dementia

NINDS : 53 Multi-infarct dementia (MID) is a common cause of memory loss in the elderly.  MID is caused by multiple strokes (disruption of blood flow to the brain).  Disruption of blood flow leads to damaged brain tissue.  Some of these strokes may occur without noticeable clinical symptoms. Doctors refer to these as “silent strokes.”  An individual having a silent stroke may not even know it is happening, but over time, as more areas of the brain are damaged and more small blood vessels are blocked, the symptoms of MID begin to appear.  MID can be diagnosed by an MRI or CT of the brain, along with a neurological examination. Symptoms include confusion or problems with short-term memory; wandering, or getting lost in familiar places; walking with rapid, shuffling steps; losing bladder or bowel control; laughing or crying inappropriately; having difficulty following instructions; and having problems counting money and making monetary transactions.  MID, which typically begins between the ages of 60 and 75, affects men more often than women. Because the symptoms of MID are so similar to Alzheimer’s disease, it can be difficult for a doctor to make a firm diagnosis.  Since the diseases often occur together, making a single diagnosis of one or the other is even more problematic.

MalaCards based summary : Vascular Dementia, also known as multi-infarct dementia, is related to binswanger's disease and dementia. An important gene associated with Vascular Dementia is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are Pathways of neurodegeneration - multiple diseases and Folate Metabolism. The drugs Cilostazol and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain.

Wikipedia : 73 Vascular dementia (VaD) is dementia caused by problems in the supply of blood to the brain, typically a... more...

Related Diseases for Vascular Dementia

Diseases related to Vascular Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 540)
# Related Disease Score Top Affiliating Genes
1 binswanger's disease 32.3 NOTCH3 MAPT APP APOE ACHE
2 dementia 31.7 TNF SERPINA3 RETREG1 PSEN1 PRNP NOTCH3
3 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 31.6 SERPINA3 NOTCH3 APP APOE
4 homocysteinemia 31.1 PON1 MTHFR CST3 APOE
5 cerebrovascular disease 31.1 TNF SERPINA3 PON1 NOTCH3 MTHFR MAPT
6 mild cognitive impairment 31.1 MTHFR MAPT CST3 CHAT BCHE APP
7 vascular disease 31.0 VEGFA TNF PON1 MTHFR IL6 CST3
8 carotid stenosis 31.0 VEGFA TNF MTHFR APOE ACE
9 cerebral amyloid angiopathy, cst3-related 30.9 SERPINA3 PSEN1 PRNP MAPT CST3 APP
10 lipid metabolism disorder 30.9 PON1 IL6 APOE ACE
11 apraxia 30.9 PSEN1 MAPT APOE
12 alzheimer disease 30.9 TNF SERPINA3 PSEN1 PRNP PON1 NEFL
13 ischemia 30.9 VEGFA PON1 APP ACE
14 chlamydia pneumonia 30.8 TNF IL6 APOE
15 arteriolosclerosis 30.8 SERPINA3 NOTCH3 MAPT APP APOE
16 arteriosclerosis 30.8 PON1 IL6 CST3 APOE ACE
17 alexia 30.8 PRNP MAPT BCHE APOE
18 transient cerebral ischemia 30.7 NOTCH3 MTHFR MAPT ACHE
19 aphasia 30.7 PSEN1 PRNP NEFL MAPT APP APOE
20 temporal arteritis 30.7 TNF SERPINA3 IL6
21 visual agnosia 30.7 PSEN1 MAPT APOE
22 subjective cognitive decline 30.6 MAPT APOE
23 head injury 30.6 CHAT APOE
24 congestive heart failure 30.6 VEGFA TNF IL6 ACE
25 agraphia 30.6 PRNP MAPT APOE ACHE
26 atherosclerosis susceptibility 30.6 VEGFA TNF PON1 MTHFR IL6 APOE
27 sleep apnea 30.5 VEGFA TNF IL6 APOE ACE
28 ideomotor apraxia 30.5 PRNP MAPT BCHE APOE
29 frontotemporal dementia 30.5 PSEN1 PRNP NEFL MAPT BCHE APP
30 finger agnosia 30.5 MBP MAPT
31 peripheral vascular disease 30.5 VEGFA MTHFR IL6 ACE
32 coronary heart disease 1 30.5 PON1 APOE ACE
33 mental depression 30.5 TNF SERPINA3 IL6
34 normal pressure hydrocephalus 30.5 VEGFA SERPINA3 PSEN1 MAPT APP APOE
35 anxiety 30.5 TNF IL6 APP APOE ACHE ACE
36 anosognosia 30.5 PSEN1 APOE
37 syphilis 30.5 TNF SERPINA3 IL6 ACE
38 amnestic disorder 30.4 PSEN1 MAPT CHAT BCHE APP APOE
39 central nervous system vasculitis 30.4 VEGFA TNF SERPINA3 IL6
40 cerebral degeneration 30.4 SERPINA3 NOTCH3 MBP APP APOE
41 alzheimer disease 10 30.4 MAPT APOE ACHE
42 sleep disorder 30.4 TNF MAPT IL6 BCHE APOE ACE
43 semantic dementia 30.3 PSEN1 MAPT APOE
44 acute cystitis 30.3 TNF SERPINA3 IL6 CST3 ACE
45 antiphospholipid syndrome 30.3 TNF PON1 MTHFR
46 nominal aphasia 30.2 PSEN1 MAPT APOE ACHE
47 huntington disease 30.2 VEGFA PRNP MAPT CHAT APP ACHE
48 glucose metabolism disease 30.2 VEGFA TNF SERPINA3 IL6 APOE ACE
49 purpura 30.2 TNF IL6 ACE
50 bronchopneumonia 30.2 TNF SERPINA3 IL6

Comorbidity relations with Vascular Dementia via Phenotypic Disease Network (PDN):


Acute Cystitis Cerebral Atherosclerosis
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Vascular Dementia:



Diseases related to Vascular Dementia

Symptoms & Phenotypes for Vascular Dementia

MGI Mouse Phenotypes related to Vascular Dementia:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 ACE ACHE APOE APP CHAT IL6
2 homeostasis/metabolism MP:0005376 10.48 ACE ACHE APOE APP BCHE CHAT
3 growth/size/body region MP:0005378 10.39 ACE ACHE APOE APP CHAT IL6
4 cardiovascular system MP:0005385 10.38 ACE ACHE APOE APP CHAT CST3
5 mortality/aging MP:0010768 10.38 ACE ACHE APOE APP BCHE CHAT
6 cellular MP:0005384 10.34 APOE APP CST3 IL6 MAPT MBP
7 nervous system MP:0003631 10.33 ACE ACHE APOE APP CHAT CST3
8 hematopoietic system MP:0005397 10.31 ACE ACHE APOE APP IL6 MAPT
9 integument MP:0010771 10.29 APOE APP IL6 MAPT MTHFR NOTCH3
10 muscle MP:0005369 10.23 ACHE APOE APP CHAT CST3 IL6
11 reproductive system MP:0005389 10.13 ACE ACHE APOE APP BCHE CHAT
12 limbs/digits/tail MP:0005371 10.1 APOE APP CHAT MTHFR PRNP PSEN1
13 neoplasm MP:0002006 9.98 ACE CST3 IL6 MAPT NOTCH3 TNF
14 no phenotypic analysis MP:0003012 9.97 ACHE APOE APP MAPT MTHFR PRNP
15 normal MP:0002873 9.97 APP CHAT MAPT MBP NEFL NOTCH3
16 respiratory system MP:0005388 9.76 ACHE APOE CHAT IL6 NOTCH3 PSEN1
17 skeleton MP:0005390 9.7 APOE APP CHAT IL6 MTHFR NOTCH3
18 vision/eye MP:0005391 9.44 ACE ACHE APOE CHAT IL6 MAPT

Drugs & Therapeutics for Vascular Dementia

Drugs for Vascular Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
6
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
7
Cerebrolysin Experimental Phase 4 12656-61-0
8
Corticosterone Experimental Phase 4 50-22-6 5753
9 Neuroprotective Agents Phase 4
10 Protective Agents Phase 4
11 Platelet Aggregation Inhibitors Phase 4
12 Respiratory System Agents Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Fibrinolytic Agents Phase 4
15 Phosphodiesterase 3 Inhibitors Phase 4
16 Bronchodilator Agents Phase 4
17 Phosphodiesterase Inhibitors Phase 4
18 Analgesics, Non-Narcotic Phase 4
19 Analgesics Phase 4
20 Antirheumatic Agents Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 Antipyretics Phase 4
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4
24 Pharmaceutical Solutions Phase 4
25 Narcotics Phase 4
26 Acetaminophen, hydrocodone drug combination Phase 4
27 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
28 Analgesics, Opioid Phase 4
29 Opiate Alkaloids Phase 4
30 Antitussive Agents Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Fluorodeoxyglucose F18 Phase 4
33
Methylphenidate Approved, Investigational Phase 2, Phase 3 113-45-1 4158
34
Galantamine Approved Phase 3 357-70-0 9651
35
Risperidone Approved, Investigational Phase 3 106266-06-2 5073
36
Haloperidol Approved Phase 3 52-86-8 3559
37
Rivastigmine Approved, Investigational Phase 3 123441-03-2 77991
38
Citalopram Approved Phase 3 59729-33-8 2771
39
Perphenazine Approved Phase 3 58-39-9 4748
40
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
41
Memantine Approved, Investigational Phase 3 19982-08-2 4054
42
Donepezil Approved Phase 3 120014-06-4 3152
43
Amlodipine Approved Phase 3 88150-42-9 2162
44
Telmisartan Approved, Investigational Phase 3 144701-48-4 65999
45
Indapamide Approved Phase 3 26807-65-8 3702
46
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 11128-99-7, 4474-91-3 172198
47
Dexetimide Withdrawn Phase 3 21888-98-2
48 Central Nervous System Stimulants Phase 2, Phase 3
49 Dopamine Uptake Inhibitors Phase 2, Phase 3
50 Psychotropic Drugs Phase 3

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia and Mixed Vascular and Alzheimer's Dementia Unknown status NCT00229333 Phase 4 Escitalopram
2 An Open Label Study on the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
3 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Completed NCT00847860 Phase 4 Cilostazol;Aspirin
4 A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
5 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4 hydrocodone/APAP w placebo PRN;hydrocodone/APAP;placebo with hydrocodone/APAP PRN
6 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
7 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
8 MIND Diet Intervention to Prevent Alzheimer's Disease Unknown status NCT02817074 Phase 3
9 Symptomatic Treatment of Vascular Cognitive Impairment Unknown status NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
10 A Randomized 26-Week, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia Completed NCT00035191 Phase 3 galantamine
11 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia Completed NCT00253123 Phase 3 risperidone
12 Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference Completed NCT00249145 Phase 3 risperidone
13 Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial Completed NCT00249158 Phase 3 Risperidone
14 A Multicenter, Double-Blind, Randomized, Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Agitation Associated With Dementia. Completed NCT00621647 Phase 3 Quetiapine Fumarate;Quetiapine Fumarate;Placebo
15 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00099216 Phase 3 Rivastigmine
16 An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00130338 Phase 3 Rivastigmine
17 A Phase III, Multicenter, Randomized, Double-blind, Positive /Placebo Controlled, Parallel, Three Arms Study of Tianzhi Granule in Mild to Moderate Vascular Dementia Completed NCT02453932 Phase 3 Tianzhi granule and placebo identified to donepezil;Donepezil and placebo identified to Tianzhi granule;Placebo
18 A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease Completed NCT00165737 Phase 3 Donepezil Hydrochloride
19 Serotonergic Pharmacotherapy for Agitation of Dementia Completed NCT00009204 Phase 3 Citalopram [Celexa];Perphenazine [Trilafon]
20 GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title Completed NCT00209456 Phase 3 DatSCAN
21 The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia Completed NCT00261573 Phase 3 galantamine hydrobromide
22 Multi-center Open Comparative Randomized Study of Efficacy and Safety of Akatinol Memantine 20 mg (Single-doses) vs. Akatinol Memantine 10 mg (Double-doses) in Patients With Moderate and Moderately Severe Vascular Dementia Recruiting NCT03986424 Phase 3 Akatinol Memantine 20 mg;Akatinol Memantine 10 mg
23 A Multi-center, Random, Double Blind and Placebo Control Phase III Clinical Study on the Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Recruiting NCT03804229 Phase 3 Butylphthalide soft capsule;Placebo soft capsule
24 A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel, and Multi-centre Study to Evaluate the Clinical Efficacy and Safety of SaiLuoTong (SLT) in the Treatment of Vascular Dementia Recruiting NCT03789760 Phase 3 SaiLuoTong capsule;placebo
25 Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Prospecta in the Treatment of Cognitive, Behavioural and Psychiatric Disorders in Patients With Vascular Dementia. Recruiting NCT04552041 Phase 3 Prospecta;Placebo
26 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Recruiting NCT03682185 Phase 3
27 An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia Terminated NCT00174382 Phase 3 Donepezil
28 Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study Terminated NCT03785067 Phase 3 telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg;Placebo oral capsule
29 Phase 2 Clinical Trial of SaiLuoTong Capsule for Vascular Dementia:A 26-week, Multicentre, Randomized, Double -Blind, Placebo-controlled Trial With a 26-week Open-label Extension Unknown status NCT01978730 Phase 2 high dose group of SaiLuoTong capsule;low dose group of SaiLuoTong;the control group
30 Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL Unknown status NCT01361763 Phase 2 Dabigatran;Antiplatelets
31 Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects Unknown status NCT01466543 Phase 2 Zydena (Udenafil);Placebo
32 Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial Unknown status NCT02450253 Phase 2 Tadalafil;Placebo
33 The Safety and Efficacy of Fufangdanshen Tablets in Treatment of Mild to Moderate Vascular Dementia: a 24-week, Double Blind, Randomized, Parallel,Placebo Controlled Trial. Completed NCT01761227 Phase 2 Fufangdanshen Tablets;Placebo
34 A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel, Comparative, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) Completed NCT01475578 Phase 2 STA-1;Ergoloid Mesylates tablet
35 A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia Completed NCT02886494 Phase 2 BAC;Matched placebo
36 Efficacy and Safety of Twice Daily TMBCZG in Mild to Moderate Vascular Dementia: Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Trial Completed NCT03230071 Phase 2 TMBCZG
37 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment Completed NCT03538522 Phase 2 N-831(Traneurocin) 10 mg QD;NA-831 (Traneurocin) 20 mg QD;NA-831 (Traneurocin) 40 mg QD;Placebo oral capsule QD
38 A Phase II Trial to Study the Effect of Metformin on AD Biomarkers: A Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Cognitive, Physiological and Biochemical Biomarkers of MCI and Dementia Due to AD Completed NCT01965756 Phase 2 Metformin;Placebos
39 DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia Completed NCT02103673 Phase 2 DAOIB;Placebo
40 Efficacy and Safety of Delta-9-tetrahydrocannabinol (∆9-THC) in Behavioural Disturbances and Pain in Dementia Completed NCT01608217 Phase 2 delta-9-tetrahydrocannabinol (delta-THC);Placebo;Acetaminophen;Acetaminophen
41 Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression Recruiting NCT04753970 Phase 1, Phase 2 Cilostazol
42 A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Recruiting NCT04658823 Phase 2 HOV-12020 (Palm tocotrienols complex);Placebo
43 Trial of Remote Ischemic Pre-Conditioning in Vascular Cognitive Impairment Recruiting NCT04109963 Phase 2
44 The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome Recruiting NCT04572477 Phase 2 [18F]THK-5351;[18F]AV-45
45 Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA,FAVORITE Recruiting NCT03891277 Phase 2 Ferrous succinate
46 Omega 3 PUFA for the Vascular Component of Age-related Cognitive Decline Active, not recruiting NCT01953705 Phase 2 Omega 3 PUFA;Placebo
47 A Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Not yet recruiting NCT04334408 Phase 2 Fremanezumab;Placebo
48 A Noval Tau Tracer ([18F]PM-PBB3) in Young Onset Dementia: Clinical and Neuroimaging Study Not yet recruiting NCT04248270 Phase 1, Phase 2 18F-PM-PBB3
49 A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia Withdrawn NCT02467413 Phase 2 BAC
50 Managing Vascular Dementia Risk Factors With SymTrend Unknown status NCT03702543 Phase 1

Search NIH Clinical Center for Vascular Dementia

Cochrane evidence based reviews: dementia, vascular

Genetic Tests for Vascular Dementia

Anatomical Context for Vascular Dementia

MalaCards organs/tissues related to Vascular Dementia:

40
Brain, Endothelial, Cortex, Temporal Lobe, Heart, Smooth Muscle, Thyroid

Publications for Vascular Dementia

Articles related to Vascular Dementia:

(show top 50) (show all 7333)
# Title Authors PMID Year
1
Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. 54 6 61
11273064 2001
2
TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. 6 61
15895461 2005
3
Differences between clinical subspecialties in the outpatient evaluation and treatment of dementia in an academic medical center. 61 54
20110698 2010
4
Vascular dementia and Alzheimer's disease - are we in a dead-end road? 61 54
20173341 2010
5
Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. 61 54
19433439 2009
6
Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL. 54 61
19359623 2009
7
Choline acetyltransferase activity in vascular dementia and stroke. 61 54
19776575 2009
8
Association between a genetic variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia. 54 61
19641318 2009
9
Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. 54 61
19221426 2009
10
Enhanced L-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. 54 61
18537053 2008
11
Sporadic vascular dementia as clinical presentation of a new missense mutation within exon 7 of NOTCH3 gene. 54 61
18499132 2008
12
Galantamine and carbon monoxide protect brain microvascular endothelial cells by heme oxygenase-1 induction. 61 54
18174021 2008
13
Lack of association between apolipoprotein E polymorphism and vascular dementia in Koreans. 61 54
18287165 2008
14
What is the relationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia? 61 54
17539949 2007
15
Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. 61 54
17395712 2007
16
Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. 54 61
17195931 2007
17
Apolipoprotein E genotypes in hospitalized elderly patients with vascular dementia. 61 54
17374951 2007
18
Presenilin gene predisposes to late-onset degenerative but not vascular dementia: a comparative study of PS1 and ApoE genes in a North Indian Cohort. 54 61
17627113 2007
19
Treatment of vascular dementia and vascular cognitive impairment. 54 61
17215726 2007
20
Absence of association between codon 129 and 219 polymorphisms of the prion protein gene and vascular dementia. 61 54
17570906 2007
21
Diabetes mellitus and dementia. 61 54
17110895 2006
22
Cortical neuronal apoptosis in CADASIL. 61 54
17008611 2006
23
Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia. 61 54
16465461 2006
24
Interventions for heart disease and their effects on Alzheimer's disease. 54 61
16945215 2006
25
Lipid metabolism in cognitive decline and dementia. 54 61
16410024 2006
26
Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. 61 54
16870640 2006
27
Cognitive frailty: Predementia syndrome and vascular risk factors. 54 61
16023766 2006
28
Haplotype analysis of single nucleotide polymorphisms in VEGF gene for vascular dementia. 54 61
16583410 2006
29
Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia. 54 61
16555084 2006
30
[Expression levels of APP and PS1 genes in patients with Alzheimer's disease]. 54 61
16735229 2006
31
Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline. 61 54
16702784 2006
32
Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? 61 54
16461472 2006
33
Apolipoprotein E epsilon4 allele frequency in vascular dementia. 54 61
16645276 2006
34
Apolipoprotein E epsilon4 allele is associated with vascular dementia. 61 54
16926537 2006
35
Two novel mutations of the NOTCH3 gene in Korean patients with CADASIL. 61 54
16256149 2006
36
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 54 61
15990115 2005
37
CADASIL mutations impair Notch3 glycosylation by Fringe. 61 54
15857853 2005
38
Noninfarct vascular dementia and Alzheimer dementia spectrum. 61 54
15760616 2005
39
Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia. 61 54
15677868 2005
40
Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. 61 54
16192723 2005
41
Absence of cholinergic deficits in "pure" vascular dementia. 54 61
15642917 2005
42
[The effect of rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years]. 61 54
15654671 2004
43
Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients. 54 61
15633941 2004
44
[Vascular dementia]. 54 61
15224429 2004
45
Apolipoprotein E polymorphism in ischemic cerebrovascular diseases and vascular dementia patients in Taiwan. 54 61
15084782 2004
46
Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. 61 54
14991454 2004
47
Apolipoprotein E gene polymorphism in Indian patients with Alzheimer's disease and vascular dementia. 54 61
14739533 2004
48
Common polymorphisms in methylenetetrahydrofolate reductase (MTHFR): relationships with plasma homocysteine concentrations and cognitive status in elderly northern italian subjects. 54 61
15207432 2004
49
Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia. 54 61
14586274 2003
50
Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. 61 54
14561434 2003

Variations for Vascular Dementia

ClinVar genetic disease variations for Vascular Dementia:

6 (show all 16)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NOTCH3 NM_000435.3(NOTCH3):c.323G>A (p.Cys108Tyr) SNV Likely pathogenic 872948 GRCh37:
GRCh38:
2 TNF NM_000594.3(TNF):c.-1037C>T SNV risk factor 12389 rs1799724 GRCh37: 6:31542482-31542482
GRCh38: 6:31574705-31574705
3 ITM2B NM_021999.5(ITM2B):c.193C>T (p.Leu65Phe) SNV Uncertain significance 872947 GRCh37:
GRCh38:
4 TMEM106B NM_001134232.2(TMEM106B):c.115G>C (p.Asp39His) SNV Uncertain significance 872951 GRCh37:
GRCh38:
5 KRIT1 NM_194454.3(KRIT1):c.1565T>C (p.Ile522Thr) SNV Uncertain significance 872943 rs758188972 GRCh37:
GRCh38:
6 PSEN2 NM_000447.3(PSEN2):c.53C>T (p.Thr18Met) SNV Uncertain significance 872950 GRCh37:
GRCh38:
7 C1R NM_001733.7(C1R):c.336G>C (p.Met112Ile) SNV Uncertain significance 625897 rs139531404 GRCh37: 12:7242740-7242740
GRCh38: 12:7090144-7090144
8 NPPA NM_006172.4(NPPA):c.377G>A (p.Arg126Gln) SNV Uncertain significance 872949 rs1803268 GRCh37:
GRCh38:
9 NOTCH3 NM_000435.3(NOTCH3):c.2149C>T (p.Arg717Cys) SNV Uncertain significance 804628 rs144163298 GRCh37: 19:15296215-15296215
GRCh38: 19:15185404-15185404
10 HTRA1 NM_002775.5(HTRA1):c.961G>A (p.Ala321Thr) SNV Uncertain significance 180746 rs587776449 GRCh37: 10:124266390-124266390
GRCh38: 10:122506874-122506874
11 COL4A2-AS1 , COL4A2 NM_001846.4(COL4A2):c.4291C>T (p.Arg1431Cys) SNV Uncertain significance 71669 rs139124960 GRCh37: 13:111156500-111156500
GRCh38: 13:110504153-110504153
12 COL4A1 NM_001845.6(COL4A1):c.401C>T (p.Pro134Leu) SNV Uncertain significance 872946 rs140517831 GRCh37:
GRCh38:
13 COL4A1 NM_001845.6(COL4A1):c.2440G>A (p.Gly814Arg) SNV Uncertain significance 872945 GRCh37:
GRCh38:
14 CCM2 NM_031443.4(CCM2):c.1283T>G (p.Ile428Ser) SNV Uncertain significance 872944 GRCh37:
GRCh38:
15 CACNA1A NM_001127222.2(CACNA1A):c.1348T>C (p.Ser450Pro) SNV Uncertain significance 434559 rs1308599413 GRCh37: 19:13428133-13428133
GRCh38: 19:13317319-13317319
16 APP NM_000484.4(APP):c.1795G>A (p.Glu599Lys) SNV Uncertain significance 585430 rs140304729 GRCh37: 21:27284167-27284167
GRCh38: 21:25911855-25911855

Expression for Vascular Dementia

Search GEO for disease gene expression data for Vascular Dementia.

Pathways for Vascular Dementia

Pathways related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.31 TNF PSEN1 PRNP NEFL MAPT IL6
2
Show member pathways
12.05 TNF SERPINA3 MTHFR IL6 APOE
3 12.02 VEGFA TNF IL6 CHAT
4 11.83 TNF PSEN1 MAPT APP APOE
5 11.81 PSEN1 PRNP NOTCH3 NEFL MBP MAPT
6 11.65 VEGFA NEFL CHAT
7
Show member pathways
11.54 VEGFA TNF IL6
8 11.46 PRNP MAPT APP
10 11.32 TNF IL6 APOE
11 11.23 TNF NEFL CST3
12 11.14 APP APOE ACE
13 11.11 PSEN1 MAPT APP APOE
14 11.1 TNF MTHFR IL6
15 11.03 CHAT BCHE ACHE
16 10.96 VEGFA PRNP APP
17 10.62 PSEN1 CST3 APP ACE
18 10.4 CHAT ACHE

GO Terms for Vascular Dementia

Cellular components related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.99 PSEN1 MTHFR MBP CHAT APP ACHE
2 extracellular space GO:0005615 9.9 VEGFA TNF SERPINA3 PON1 IL6 CST3
3 neuron projection GO:0043005 9.88 PSEN1 NEFL MAPT CHAT APP
4 endoplasmic reticulum lumen GO:0005788 9.77 IL6 CST3 BCHE APP APOE
5 growth cone GO:0030426 9.73 PSEN1 NEFL MAPT APP
6 membrane raft GO:0045121 9.72 TNF PSEN1 PRNP MAPT APP
7 blood microparticle GO:0072562 9.71 SERPINA3 PON1 BCHE APOE
8 platelet alpha granule lumen GO:0031093 9.67 VEGFA SERPINA3 APP
9 neuromuscular junction GO:0031594 9.56 PSEN1 NEFL APP ACHE
10 cell surface GO:0009986 9.56 VEGFA TNF PSEN1 PRNP NOTCH3 MBP
11 nuclear envelope lumen GO:0005641 9.52 BCHE APP
12 main axon GO:0044304 9.46 MAPT APP
13 extracellular region GO:0005576 9.44 VEGFA TNF SERPINA3 PON1 NOTCH3 MAPT

Biological processes related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.08 VEGFA TNF PSEN1 IL6 APP
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 VEGFA TNF APP APOE
3 positive regulation of protein phosphorylation GO:0001934 9.94 VEGFA TNF PSEN1 APP
4 negative regulation of endopeptidase activity GO:0010951 9.9 SERPINA3 PRNP CST3 APP
5 negative regulation of neuron apoptotic process GO:0043524 9.88 RETREG1 PSEN1 NEFL APOE
6 cellular protein metabolic process GO:0044267 9.88 PSEN1 IL6 CST3 APP APOE
7 neuron projection development GO:0031175 9.86 MAPT IL6 APP APOE
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 VEGFA TNF IL6
9 response to oxidative stress GO:0006979 9.85 PSEN1 PRNP APP APOE
10 positive regulation of protein binding GO:0032092 9.83 PSEN1 APP ACE
11 response to glucocorticoid GO:0051384 9.82 TNF IL6 BCHE
12 synapse organization GO:0050808 9.8 PSEN1 MAPT APP
13 positive regulation of MAP kinase activity GO:0043406 9.8 VEGFA TNF PSEN1
14 positive regulation of interleukin-6 production GO:0032755 9.8 TNF MBP IL6 APP
15 positive regulation of interleukin-1 beta production GO:0032731 9.79 TNF IL6 APP
16 cellular response to amyloid-beta GO:1904646 9.78 PSEN1 PRNP APP
17 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.76 VEGFA TNF IL6 APP
18 positive regulation of chemokine production GO:0032722 9.74 TNF IL6 APP
19 learning or memory GO:0007611 9.73 PSEN1 PRNP MAPT APP
20 positive regulation of phosphorylation GO:0042327 9.71 VEGFA PSEN1 APP
21 microglial cell activation GO:0001774 9.7 TNF MAPT APP
22 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.68 TNF MBP
23 axonal transport of mitochondrion GO:0019896 9.68 NEFL MAPT
24 neutrophil mediated immunity GO:0002446 9.67 IL6 ACE
25 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.67 PSEN1 APP
26 response to folic acid GO:0051593 9.66 MTHFR BCHE
27 locomotion GO:0040011 9.66 PSEN1 NEFL
28 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
29 vascular endothelial growth factor production GO:0010573 9.63 TNF IL6
30 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.61 VEGFA ACE
31 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.59 PSEN1 APP
32 astrocyte activation involved in immune response GO:0002265 9.58 PSEN1 APP
33 negative regulation of long-term synaptic potentiation GO:1900272 9.58 PRNP APP APOE
34 amyloid precursor protein metabolic process GO:0042982 9.54 PSEN1 APOE ACHE
35 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.51 PSEN1 APP
36 neuron projection maintenance GO:1990535 9.5 PSEN1 PRNP APP
37 negative regulation of gene expression GO:0010629 9.5 VEGFA TNF PSEN1 MAPT APP APOE
38 modulation of age-related behavioral decline GO:0090647 9.43 PSEN1 PRNP APP
39 positive regulation of amyloid fibril formation GO:1905908 9.33 PSEN1 APP APOE
40 astrocyte activation GO:0048143 8.92 TNF PSEN1 MAPT APP

Molecular functions related to Vascular Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.56 TNF PRNP MBP CST3
2 growth factor receptor binding GO:0070851 9.4 PSEN1 APP
3 lipoprotein particle binding GO:0071813 9.37 MAPT APOE
4 identical protein binding GO:0042802 9.36 VEGFA TNF PRNP NOTCH3 NEFL MAPT
5 amyloid-beta binding GO:0001540 9.35 PRNP CST3 BCHE APOE ACHE
6 cholinesterase activity GO:0004104 9.32 BCHE ACHE
7 acetylcholinesterase activity GO:0003990 9.16 BCHE ACHE

Sources for Vascular Dementia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....